Ö. Türeci

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

Uğur Şahin, Ö. Türeci, Georgy M. Manikhas et al. · Annals of Oncology · 2021 · 359 citations · Full text

Medicine, Oncology, Pharmacology +14

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

Ö. Türeci, Uğur Şahin, Henning Schulze‐Bergkamen et al. · Annals of Oncology · 2019 · 244 citations · Full text

Medicine, Oncology, Pharmacology +17

Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma

Martin Schüler, S-E. Al-Batran, Zanete Zvirbule et al. · Annals of Oncology · 2016 · 21 citations · Full text

Medicine, Oncology, Pharmacology +15

Efficacy and Safety of Multiple Doses of Imab362 in Patients with Advanced Gastro-Esophageal Cancer: Results of a Phase Ii Study

Tanja Trarbach, Martin Schüler, Zanete Zvirbule et al. · Annals of Oncology · 2014 · 18 citations · Full text

Medicine, Oncology, Pharmacology +12